Highest-materiality recent filing
Harmony Biosciences Q2 revenue $261.3M (+30% YoY); EPS $1.28; reiterates FY guidance $1.0-1.04B
Q2 net revenue $261.3M, up 30% YoY; average patients 8,950 (+450).
Harmony Biosciences preannounces record Q2 revenue of ~$261M, CFO steps down
Preliminary Q2 2026 WAKIX net revenue ~$261M, record quarter, up 30% YoY and 21% QoQ.
Harmony Biosciences Q1 revenue $215.4M (+17% YoY); reaffirms FY2026 guidance >$1B
Q1 net product revenue $215.4M, up 17% YoY; diluted EPS $0.55 vs $0.78 in Q1 2025.
Harmony Biosciences appoints Glenn Reicin as CFO; reaffirms 2026 revenue guidance of $1.0-$1.04B
Sandip Kapadia steps down as CFO effective April 14, 2026 to pursue other career opportunities.
Harmony Biosciences Q4 revenue $243.8M (+21% YoY); guides WAKIX to $1B+ in 2026
Full-year 2025 WAKIX revenue $868.5M, up 22% YoY; Q4 GAAP EPS $0.38, adjusted EPS $0.57.
Harmony Biosciences reports ~$868M FY2025 WAKIX revenue; guides $1.0-1.04B in 2026
Preliminary Q4 2025 WAKIX net revenue ~$243M; FY2025 ~$868M, up ~21% YoY.
Harmony Biosciences Q3 revenue $239.5M (+29% YoY); raises FY2025 guidance to $845-865M
Q3 net revenue $239.5M (WAKIX), +29% YoY; GAAP EPS $0.87, adjusted EPS $1.08.
Harmony Biosciences raises 2025 revenue guidance after Q3 WAKIX revenue of $239M (+29% YoY)
Preliminary Q3 2025 WAKIX net revenue of ~$239M, up 29% year-over-year.
Harmony Biosciences' Phase 3 ZYN002 trial in Fragile X syndrome fails primary endpoint
RECONNECT study did not meet primary endpoint of improvement in social avoidance; higher than expected placebo response cited.
Harmony Biosciences Q2 revenue $200.5M (+16% YoY); EPS $0.68; reaffirms FY guidance $820-860M
Net product revenue $200.5M (+16% YoY); GAAP net income $39.8M ($0.68 diluted EPS); non-GAAP adj. net income $53.8M ($0.92 diluted EPS).
Harmony settles Lupin ANDA litigation; generic WAKIX entry delayed to 2030
Lupin receives license to launch generic WAKIX no earlier than January 2030 (July 2030 with pediatric exclusivity).
Harmony Biosciences reports 20% Q1 revenue growth; reaffirms 2025 guidance $820-860M
Q1 net revenue $184.7M, +20% YoY; GAAP net income $45.6M ($0.78 diluted EPS).
Harmony Biosciences names Takeda veteran Adam Zaeske as CCO; Dierks steps down
Jeffrey Dierks steps down as CCO effective March 31, 2025; receives $476,215 cash and accelerated vesting for 2025 awards.
Harmony Biosciences Q4 2024 net revenue $201.3M, FY $714.7M; guides 2025 $820-860M
Q4 2024 net product revenue $201.3M (+20% YoY); FY 2024 net revenue $714.7M (+23% YoY).
Harmony Biosciences: Q4 WAKIX revenue ~$201M, FY2024 ~$714M; guides 2025 $820-860M
Preliminary Q4 2024 net product revenue ~$201M (vs $168.4M Q4 2023); FY2024 ~$714M (vs $582M, +23% YoY).
Secondary offering of 8M shares by certain shareholders; company receives no proceeds
Selling Shareholders sold 8,000,000 shares of common stock in a registered public offering.
Harmony Biosciences Q3 net revenue $186M (+16% YoY); reiterates FY2024 guidance $700-720M
GAAP net income $46.1M ($0.79 diluted EPS) vs $38.5M ($0.63) in Q3 2023; non-GAAP adjusted EPS $1.03.
Harmony Biosciences highlights best-in-class orexin-2 agonist, $3B revenue goal at Investor Day
BP1.15205 orexin-2 agonist shows highest potency vs. all publicly disclosed competitors, potential best-in-class.
Harmony Q2 net revenue $172.8M (+29% YoY); non-GAAP EPS $1.05 vs $0.76; FY guidance reaffirmed
Net product revenue $172.8M for Q2 2024, up 29% from $134.2M in Q2 2023.
Harmony Biosciences Q1 revenue $154.6M (+30% YoY); reaffirms FY2024 guidance $700-720M
Q1 net revenue $154.6M (+30% YoY); GAAP EPS $0.67, adjusted EPS $0.88.
Harmony Biosciences obtains exclusive license for orexin-2 receptor agonist from Bioprojet
Upfront fee $25.5M; development/regulatory milestones up to $127.5M, sales milestones up to $240M.
Harmony Biosciences Q4 2023 revenue $168.4M, guides 2024 revenue $700-720M
WAKIX net revenue $168.4M in Q4 2023 (+31% YoY); full year $582.0M (+33%).
Harmony Biosciences reports Q4 net product revenue ~$168M, FY2023 ~$582M; 2024 guidance $700-720M
Preliminary Q4 net product revenue ~$168M, up ~31% YoY; FY2023 ~$582M, up ~33% YoY.
Harmony files Zynerba FY2022 audited financials; net loss $35M, accumulated deficit $274.5M
Zynerba FY2022 net loss $35.0M ($0.82 loss per share); no revenue; R&D expense $21.1M, G&A $14.2M.
Net product revenue $160.3M (+37% YoY); average WAKIX patients ~5,800 (+350 sequentially).
Phase 3 INTUNE study for pitolisant in idiopathic hypersomnia misses primary endpoint
Primary endpoint (ESS change) did not reach statistical significance between pitolisant and placebo in the randomized withdrawal phase.
Harmony Biosciences completes acquisition of Zynerba for $60M cash plus up to $140M in CVRs
Purchase price of $1.1059 per share in cash (approx. $60M aggregate) plus one CVR per share worth up to $2.5444.
Harmony Biosciences receives generic challenge notices for WAKIX from Novugen and Lupin
Novugen Pharma and Lupin Ltd. filed ANDAs seeking FDA approval to market generic pitolisant (WAKIX) before patent expiry.
Harmony Biosciences to acquire Zynerba for $1.1059 cash + CVR up to $2.5444 per share
Total potential consideration up to ~$3.65/share: $1.1059 cash plus a CVR worth up to $2.5444 upon milestones.
Harmony Biosciences Q2 net revenue $134.2M, up 25% YoY; board approves $125M buyback
Q2 net revenue $134.2M vs $107.0M YoY (+25%); GAAP net income $34.3M ($0.56 diluted EPS).
Harmony Bio refinances with $185M term loan, repays $196.5M debt, saves ~$6M/year interest
New $185M senior secured term loan from JPMorgan-led syndicate, matures July 26, 2028.
Harmony Bio Q1 WAKIX revenue $119.1M (+40% YoY); GAAP EPS $0.48; patients ~5,200
Net product revenue $119.1M, +39.6% YoY; GAAP net income $29.5M ($0.48 diluted EPS) vs $21.5M ($0.35) prior year.
Harmony Biosciences accelerates Phase 3 INTUNE enrollment; topline data expected Q4 2023
Enrollment completion expected Q2 2023, just over one year from trial initiation.
Harmony Biosciences Q4 2022 net revenue $128.3M (+41% YoY); full-year net income $181.5M
Q4 net product revenue $128.3M, up 41% YoY; average patients on WAKIX ~4,900.
On July 16, 2026, the Company announced that Glenn Reicin, the Company’s Chief Financial Officer, will be stepping down as the Company’s Chief Financial Officer effective as of July 16, 2026 to pursue other career opportunities.
On July 16, 2026, the Board of Directors of the Company appointed Stephen Mollichella, the Company’s Senior Vice President and Controller, as Interim Principal Financial Officer of the Company, effective as of July 16, 2026.
Effective April 2, 2025, the Board of Directors (the “Board”) of Harmony Biosciences Holdings, Inc. (the “Company”) appointed Ron Philip, age 51, as a Class III director, filling the previously announced vacancy in the Board created by the resignation of Jack Bech Nielsen effective June 27, 2024.
Jeffrey Dierks will be departing from the Company as its Chief Commercial Officer, effective as of March 31, 2025 (the “Effective Date”), for personal reasons.
On June 27, 2024, Jack Bech Nielsen notified the Board of Directors (the “Board”) of Harmony Biosciences Holdings, Inc. (the “Company”) that he is resigning from the Board effective immediately, due to health reasons.
appointed Kumar Budur, M.D., M.S., the Company’s Chief Medical Officer, to the title of Executive Vice President and Chief Medical & Scientific Officer (the “Appointment”), effective on May 1, 2024
appointed Peter Anastasiou as a Class III director of the Company with an initial term expiring at the Company’s 2026 annual meeting of stockholders, effective immediately.
The Board of Directors of Harmony Biosciences Holdings, Inc. (the “Company”) appointed Sandip Kapadia, the Company’s Chief Financial Officer, to the title of Chief Financial Officer and Chief Administrative Officer, effective upon Mr. Kapadia’s acceptance on September 30, 2023.
Dr. Jeffrey M. Dayno, the Company’s current Interim President and Chief Executive Officer and Chief Medical Officer, has been appointed by the Board of Directors of the Company (the “Board”) as President and Chief Executive Officer (“CEO”) of the Company.
Dr. Dayno has also been appointed to the Board as a Class I Director
Jeffrey S. Aronin, who has served at the Company’s Executive Chairman since January 2023, has returned to his prior role as non-executive Chairman of the Board, effective April 24, 2023.
the Board appointed Jeffrey S. Aronin, currently Chairman of the Board, as the Company’s Executive Chairman, effective January 6, 2023.
Max materiality 0.85 · Median 0.75 · Most common event earnings